1. Pink Sheet

Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s

 
• By Sarah Karlin-Smith

Moderna’s COVID-19 vaccine looks better than Pfizer/BioNTech’s at preventing severe disease and like it may offer some benefit in preventing asymptomatic infections, but these advantages may be short-lived and hard to capitalize on due to supply limitations.  

Moderna logo and syringe (Alex Gottschalk/DeFodi Images via Getty Images)
• Source: Alex Gottschalk/DeFodi Images via Getty Images

Moderna, Inc.’s COVID-19 vaccine will head into its 17 December US Food and Drug Administration advisory committee review with more solid data on its impact on severe disease than competitor Pfizer Inc./BioNTech SE’s had when that vaccine went in front of the same committee last week. Moderna also has some preliminary data on its vaccine’s ability to prevent transmission of the virus, of which Pfizer had none.

With an overall similar efficacy and safety profile to Pfizer’s product, Moderna is all but guaranteed to receive the second...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 
• By Bridget Silverman

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

Organ-On-A-Chip: Upcoming US FDA Guidance Could Help Flesh Out ‘Roadmap’

 
• By Michael McCaughan

The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.